Press Releases

08.04.2021
Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results
08.03.2021
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07.28.2021
Iveric Bio to Report Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
07.26.2021
Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule
07.19.2021
Iveric Bio Appoints Christopher Simms as Chief Commercial Officer
07.12.2021
IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
07.12.2021
IVERIC bio, Inc. Announces Proposed Offering of Common Stock
07.06.2021
Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
06.18.2021
Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium for Investors
06.09.2021
Iveric Bio to Host Investor Symposium on Dry Age-Related Macular Degeneration on June 18, 2021